Allogeneic stem cell transplantation for the treatment of advanced solid tumors

Bregni, Marco; Bernardi, Massimo; Ciceri, Fabio; Peccatori, Jacopo
September 2004
Springer Seminars in Immunopathology;Sep2004, Vol. 26 Issue 1/2, p95
Academic Journal
Allogeneic stem cell transplantation has emerged as a potentially curative treatment modality for patients with hematological malignancies. The graft-versus-leukemia effect, an immune mechanism mediated by the donor immune system, is an important component of the therapeutic effect of allogeneic transplantation. Recent data from experimental animal models and from preliminary clinical experience suggest that a graft-versus-tumor effect, analogous to the graft-versus-leukemia effect, may be generated against solid tumors such as renal cell cancer, breast cancer, and other malignancies. The use of non-myeloablative, immunosuppressive conditioning regimens offers the opportunity to achieve a full-donor engraftment with reduced transplant-related complications and mortality, enabling also patients of advanced age and with co-morbidities to receive an allografting. Advanced renal cell cancer, an essentially incurable disease, has emerged from pilot studies as a disease susceptible to the graft-versus-tumor effect. Future studies will demonstrate if the tumor responses observed after allografting will translate into a clinically meaningful survival advantage. Other tumors in which tumor responses have been observed are: breast cancer, ovarian cancer, colorectal cancer, soft-tissue sarcoma, and others. Advanced melanoma may not be amenable to graft-versus-tumor effect. Future studies will point to the identification, isolation and cloning of target antigen(s) of graft-versus-tumor effect, to further reduce toxicities and to achieve a selective cell-mediated immunotherapy.


Related Articles

  • Hematopoietic Stem-Cell Transplantation. Copelan, Edward A. // New England Journal of Medicine;4/27/2006, Vol. 354 Issue 17, p1813 

    The article summarizes information surrounding hematopoietic stem cell transplantation and discusses the recent progress in the role of this procedure as far as treating malignant and nonmalignant conditions. The primary use for hematopoietic stem cell transplantations are hematologic and...

  • Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Gratwohl, A.; Schmid, O.; Baldomero, H.; Horisberger, B.; Urbano-Ispizua, A. // Bone Marrow Transplantation;Nov2004, Vol. 34 Issue 10, p855 

    Summary:This 2002 European Group for Blood and Marrow Transplantation (EBMT) activity survey concentrates on current status, increase and decrease in haematopoietic stem cell transplantation (HSCT) activity in Europe and investigates the association of transplant rates with team density. In...

  • Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis. Woodard, P.; Helton, K.; McDaniel, H.; Khan, R. B.; Thompson, S.; Hale, G.; Benaim, E.; Kasow, K.; Leung, W.; Horwitz, E.; Srivastava, D. K.; Tong, X.; Yusuf, U.; Cunningham, J. M.; Handgretinger, R. // Bone Marrow Transplantation;Jun2004, Vol. 33 Issue 11, p1151 

    Encephalopathy is a poorly characterized complication of hematopoietic stem cell transplantation (HSCT). No comprehensive report of encephalopathy exists for children, and the literature contains only a few for adults. We analyzed a large cohort of 405 pediatric patients who underwent allogeneic...

  • Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Cordonnier, C.; Maury, S.; Esperou, H.; Pautas, C.; Beaune, J.; Rodet, M.; Lagrange, J.-L.; Rouard, H.; Beaumont, J.-L.; Bassompierre, F.; Glückman, E.; Kuentz, M.; Durand-Zaleski, I. // Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p649 

    Summary:Allogeneic hematopoietic stem cell transplantation (SCT) is a widely used, cost-intensive procedure. Although pretransplant nonmyeloablative (NMA) or reduced-intensity conditioning regimens appear very promising, prospective studies comparing this approach with the conventional...

  • Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Khan, F.; Agarwal, A.; Agrawa, S. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p1 

    Summary:The main goal of post-transplantation monitoring in hematopoietic stem cell transplantation (HSCT) is to predict negative events, such as disease relapse, graft rejection and graft-versus-host disease, in order to intervene with appropriate therapy. In this context, chimerism analysis is...

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Imahashi, N; Suzuki, R; Fukuda, T; Kakihana, K; Kanamori, H; Eto, T; Mori, T; Kobayashi, N; Iwato, K; Sakura, T; Ikegame, K; Kurokawa, M; Kondo, T; Iida, H; Sakamaki, H; Tanaka, J; Kawa, K; Morishima, Y; Atsuta, Y; Miyamura, K // Bone Marrow Transplantation;Jan2013, Vol. 48 Issue 1, p56 

    Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with...

  • Emerging trends in transplantation of inherited metabolic diseases. Prasad, V. K.; Kurtzberg, J. // Bone Marrow Transplantation;Jan2008, Vol. 41 Issue 2, p99 

    Allogeneic hematopoietic stem cell transplantation (HSCT) can prolong life and improve its quality in patients with inherited metabolic diseases. HSCT offers a permanent source of enzyme replacement therapy and also might mediate nonhematopoietic cell regeneration or repair. Unrelated cord blood...

  • Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Baron, Frédéric; Storb, Rainer // Springer Seminars in Immunopathology;Sep2004, Vol. 26 Issue 1/2, p71 

    Allogeneic hematopoietic cell transplantation (HCT) was originally developed as a form of rescue from high-dose chemoradiotherapy, which is given both to eradicate malignancy and provide sufficient immunosuppression for allogeneic engraftment. The first attempts of allogeneic HCT in humans met...

  • Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Omuro, Y; Matsumoto, G; Sasaki, T; Tanaka, Y; Maeda, Y; Sakamaki, H; Hiruma, K; Tsuruta, K; Takahashi, T // Bone Marrow Transplantation;May2003, Vol. 31 Issue 10, p943 

    Summary:A 59-year-old female with an unresectable, large pancreatic tumor (10.0 x 8.0?cm2 on CT scan) underwent nonmyeloablative allogeneic peripheral-blood stem-cell transplantation from her HLA-identical sibling. Pronounced tumor regression and relief from pain without acute graft-versus-host...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics